# HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

> **NCT06978296** · NA · NOT_YET_RECRUITING · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer Metastatic Disease
- Oligometastatic Prostate Cancer (OMPC)

## Interventions

- **RADIATION:** Stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT06978296
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2027-10-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978296, "HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06978296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*